EFFECTS OF SGLT2 INHIBITORS ON CARDIAC FUNCTION IN CHRONIC HEART FAILURE
Keywords:
SGLT2 inhibitors, chronic heart failure, type 2 diabetes.Abstract
Many clinical studies have explored sodium–glucose cotransporter 2 (SGLT2) inhibitors in patients with chronic heart failure (CHF), with or without type 2 diabetes mellitus and SGLT2 inhibitors were proved to significantly reduce CHF hospitalization, cardiovascular death, cardiovascular mortality, all-cause mortality and myocardial infarction in patients with or without type 2 diabetes. However, only a limited few have investigated the effects of SGLT-2 inhibitors on HF disease-specific health status and cardiac function. This article describes to assess the effects of SGLT2 inhibitors on cardiac function in CHF patients.
Downloads
References
McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic Heart Failure. Eur Heart J. 2021; p.42.
Lippi G, Sanchis-Gomar F. Global epidemiology and future trends of heart failure. AME Med J 2020; pp.5:15.
Maack C, Lehrke M,Backs J, et al. Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association–European Society of Cardiology. Eur Heart J 2018;p.39.
Physiology Linda S. Costanzo seventh edition 2019; p.4.
Mavink.com (picture-1)
